Group 1: Fixed Income/Banking - Current oil prices are experiencing a pulse-like increase, with historical patterns showing similarities to the early 2022 Ukraine-Russia conflict, but the current price fluctuations may occur at a faster pace due to market conditions [3][11] - Supply-driven oil price increases are generally not expected to trigger monetary policy tightening, as historical experiences indicate that central banks focus on demand-side adjustments [10][11] - The bond market may experience fluctuations in March, influenced by oil prices affecting market sentiment, but long-term bond risks are considered low due to limited holdings [3][11] Group 2: Overseas/Education Research - The ongoing conflict in the Middle East is a major concern for global markets, with escalating oil prices and declining stock markets indicating investor anxiety [12][15] - The approval of a new commercial nuclear reactor in the U.S. marks a significant milestone for the nuclear energy sector, reflecting renewed policy support for advanced nuclear projects [13] - The commercial aerospace sector is expected to see revenue growth driven by government contracts and commercial agreements, despite high capital expenditures and operational losses [14][15] Group 3: Machinery/Construction - The 2026 National People's Congress emphasizes the importance of effective investment, with a focus on major infrastructure projects and the "Six Networks" initiative, which includes water and electricity networks [16][19] - The fiscal policy remains proactive, with record-high government spending and special bond issuance aimed at supporting infrastructure investments [17][19] - The construction sector is expected to benefit from stable infrastructure demand, particularly in energy security and clean energy projects [19] Group 4: Pharmaceuticals - Hutchison China MediTech reported a total revenue of $549 million for 2025, a decrease of 12.96%, while net profit surged by 1111.03% to $457 million [21][22] - The company’s oncology/immunology business generated $286 million, with significant growth in international sales, particularly for its drug, fruquintinib [22][23] - The ATTC platform is progressing into clinical validation, with multiple candidates entering trials, indicating a robust pipeline for future growth [23][24] Group 5: Home Appliances - Bosideng is expected to achieve steady revenue growth, with a projected mid-single-digit increase for the fiscal year, despite a warm winter affecting sales [26][27] - The main brand, down jackets, is anticipated to maintain growth, supported by high-profile designer collaborations [26][27] - The company is focusing on improving operational efficiency and management capabilities across its various business segments [27][28] Group 6: North Exchange - North Mining Testing is positioned as a leader in the non-ferrous metal testing sector, benefiting from rising metal prices and the domestic demand for quality control [30][31] - The testing services market is projected to reach ¥487.6 billion by 2024, with a significant shift towards larger, more concentrated firms [30][31] - The company is expanding its business model to include high-end instrument development, enhancing its competitive edge in the market [31][32]

Investment Rating - The report maintains an "Outperform" rating for the industry [5] Core Insights - The North Exchange 50 index experienced a significant decline of 12.32% in November 2025, with the index closing at 1,387.70 points [31] - The total number of listed companies on the North Exchange reached 285, with a total market capitalization of 827.155 billion and a circulating market value of 507.712 billion, reflecting a decrease of 10.2% and 11.2% respectively [11][18] - The report highlights that all sectors within the North Exchange experienced declines, with the most significant drops in household appliances, transportation, communication, automotive, and non-ferrous metals [35] Market Overview - The trading volume for November was 16.987 billion shares, with a total transaction value of 376.778 billion, marking a month-on-month increase of 9.9% in volume and 3.1% in value [18][21] - The average daily margin balance for the North Exchange in November was 7.789 billion, showing a month-on-month increase of 2.35% [22] Valuation Metrics - As of November 28, the North Exchange 50 index had a price-to-earnings ratio (PE-TTM) of 43.07, placing it at the 67.98th percentile over the past two years, while the price-to-book ratio (PB-MRQ) was 8.89, at the 75.21st percentile [24][27] - The dividend yield was reported at 0.78, corresponding to the 26.56th percentile over the same period [24] Industry Performance - The report indicates that the North Exchange's specialized and innovative index fell by 13.44% in November, with other major indices also experiencing declines, including the Sci-Tech 50 down 6.24% and the ChiNext index down 4.23% [31] - The report notes that the North Exchange's new listings included five companies: Danna Biological, Zhongcheng Consulting, Beikang Testing, Dapeng Industrial, and Nante Technology [11][3] Policy and Events - In November 2025, the Beijing Stock Exchange introduced a series of policies aimed at enhancing market vitality and solidifying institutional foundations, achieving progress in information disclosure, institutional behavior, new stock performance, and ongoing supervision [4]

IPO Review and Registration Progress - Four companies passed the IPO review last week, including two semiconductor firms, Qiangyi Co. and Hengrun Chang, aiming to list on the Sci-Tech Innovation Board and Beijing Stock Exchange respectively [2][3] - Qiangyi Co. focuses on the development and production of probe cards, essential for semiconductor testing, with a high customer concentration where the top five clients contribute about 80% of revenue [2][3] - Hengrun Chang specializes in plasma RF power systems, with revenue projected to grow from 158 million yuan in 2022 to 541 million yuan in 2024, although a slight decline in revenue is expected in 2025 due to increased R&D and capacity expansion [3][4] New IPO Applications and Upcoming Listings - Five companies are scheduled for IPO reviews this week, including Zhenstone Co., which plans to raise 3.981 billion yuan, focusing on clean energy materials [5][6] - Zhenstone's revenue is expected to decline from 5.267 billion yuan in 2022 to 4.439 billion yuan in 2024, primarily due to market competition and raw material price fluctuations [6] - Other companies like Yisiwei and Aide Technology are also preparing for IPOs, with Yisiwei's revenue heavily reliant on government subsidies [7][8] New Stock Listings and Subscription Dynamics - Three new stocks are set to be listed this week, including Beikang Detection, Hengkun New Materials, and Nanfang Network Digital, with significant revenue growth reported for Nanfang Network Digital [12][13] - Beikang Detection focuses on non-ferrous metal inspection services, while Hengkun New Materials specializes in key materials for semiconductor manufacturing [12][13] - Two new stocks are scheduled for subscription, including Jingchuang Electric and China Uranium, with China Uranium projected to achieve revenue between 19.5 billion and 20 billion yuan in 2025 [14][15]

Summary of Key Points Core Viewpoint The Beijing Stock Exchange (BSE) has seen a decrease in trading volume and value over the past week, with a total of 282 listed companies as of November 9, 2025. The market is also witnessing new listings and ongoing IPO activities, indicating a dynamic but challenging environment for investors. Trading Activity - As of November 9, 2025, the BSE has 282 listed companies with a total share capital of 39.225 billion shares and a circulating share capital of 25.056 billion shares [2] - For the week of November 3 to November 9, the trading volume was 4.925 billion shares, a decrease of 17.24% week-on-week, while the trading value was 1136.16 billion yuan, down 21.40% from the previous week [3] - The average trading price during this period was 23.07 yuan, reflecting a decrease of 5.03% [3] - The BSE 50 Index fell by 3.79% to 1522.73 points, with 9 stocks rising and 41 stocks declining [3] New Listings and IPOs - Two companies successfully listed on the BSE during the week of November 3 to November 9, 2025 [7] - The newly listed companies include: - **Danna (Tianjin) Biotechnology Co., Ltd.**: Listed on November 3, 2025, with a first-day trading surge of 497.08% and a closing price of 102.10 yuan [8][10] - **Zhongcheng Consulting Group Co., Ltd.**: Listed on November 7, 2025, with a first-day increase of 170.08% and a closing price of 35.60 yuan [13][30] - Both companies aim to raise approximately 1.37 billion yuan for various projects, including R&D and infrastructure [10][30] Financial Performance of Newly Listed Companies - **Danna Biotechnology**: - Revenue for 2022-2024: 295 million yuan, 237 million yuan, 240 million yuan; Net profit: 44.62 million yuan, 77.60 million yuan, 87.19 million yuan [10] - 2025 H1 revenue decreased by 1.38% to 116 million yuan, while net profit increased by 29.55% to 49.96 million yuan [11] - **Zhongcheng Consulting**: - Revenue for 2022-2024: 303 million yuan, 368 million yuan, 396 million yuan; Net profit: 64.36 million yuan, 81.06 million yuan, 105 million yuan [13] - 2025 H1 revenue decreased by 4.08% to 191 million yuan, and net profit decreased by 2.66% to 53.29 million yuan [14] Ongoing IPO Activities - As of November 9, 2025, there are 104 companies awaiting approval for listing on the BSE, with various stages of the IPO process [6] - Two companies submitted registration during the week, while three companies passed the listing committee meetings [25][26] - Notable companies that passed the listing committee include: - **Qilong Ocean**: Engaged in oil drilling equipment manufacturing, aiming to raise 382 million yuan [27] - **Haiseng Medical**: Focused on medical device manufacturing, seeking to raise 370 million yuan [30] - **Guoliang New Materials**: Specializing in refractory materials, aiming to raise 175 million yuan [33] Market Dynamics - The BSE is experiencing fluctuations in trading activity and new listings, reflecting both opportunities and challenges in the current market environment [3][6][25]